Category: 6. Business

• Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented
• Biomarker data informing use of investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus…

• Sustained improvements across stringent measures of disease in patients with psoriatic arthritis (PsA): One-year improvements were sustained to three years across measures of…

Introduction

Asthma is a heterogeneous respiratory disease, generally classified into Type 2 (T2) and non-Type 2 (non-T2) subtypes, characterized by chest tightness, cough, wheezing, and shortness of breath, affecting approximately 1–18% of the…

Elinzanetant (Lynkuet; Bayer) just became the most recent nonhormonal treatment approved for moderate to severe vasomotor symptoms (VMS) associated with menopause.¹ At The Menopause Society 2025 Annual Meeting, findings from multiple…

At the ESMO Congress 2025 in Berlin, Dr. Rocio Garcia-Carbonero (Madrid, Spain) presented the findings of the VIRAGE trial (2216MO) — a randomized phase IIb, open-label study evaluating the oncolytic adenovirus VCN-01 combined…

Intuitive Machines (LUNR) has drawn fresh attention as investors weigh the impact of new US export curbs on tech to China. At the same time, the company is advancing its IM-3 lunar mission and securing NASA contracts.

See our latest analysis…

Vulnerable deep-sea habitats will be mapped with the help of artificial intelligence (AI) in a study made possible by a £2m investment.

The Deep Vision project – run by Plymouth Marine Laboratory and the University of Plymouth – will study…